AZD5492 for B-Cell Lymphoma (TITANium Trial)

Phase 1 & 2

Recruiting

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG performance status of ≤ 2

≥18 years of age

Must not have

Active CNS involvement in lymphoma or CNS pathology

Prior allogeneic HSCT within 180 days, prior autologous HSCT within 90 days, or cell therapy within 90 days of start of therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up module 1 - from first dose of azd5492 up to approximately 2 years.

Awards & highlights

No Placebo-Only Group

Summary

"This trial is testing a new treatment called AZD5492 to see if it is safe and effective for people with B-cell cancers that have not responded to other treatments."

Who is the study for?

This trial is for individuals with B-Cell Malignancies that have not responded to or have returned after previous treatments. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be required to have a particular stage or type of disease.

What is being tested?

The study is testing AZD5492, an experimental T cell-engaging antibody targeting CD20. It's in early stages (Phase I/II) to see if it's safe, tolerable, and effective for treating Relapsed or Refractory B-Cell Malignancies.

What are the potential side effects?

Potential side effects are not listed; however, as with many cancer therapies, they could include immune system reactions, infusion-related responses, fatigue, nausea and potential impact on blood counts leading to increased infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can do most of my daily activities on my own.

Select...

I am 18 years old or older.

Select...

My condition worsened after two previous treatments.

Select...

My cancer is a type of B-cell lymphoma or leukemia.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My lymphoma affects my brain or spinal cord.

Select...

I haven't had a stem cell transplant or cell therapy in the last 3 to 6 months.

Select...

I have been diagnosed with a specific type of lymphoma.

Select...

I have had severe reactions to previous treatments.

Select...

I do not have any ongoing and untreated infections.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ module 1 - from first dose of azd5492 up to approximately 2 years.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~module 1 - from first dose of azd5492 up to approximately 2 years.

This trial's timeline: 3 weeks for screening, Varies for treatment, and module 1 - from first dose of azd5492 up to approximately 2 years. for reporting.